TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7488812
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for 2 months (protocol B)
Study: 7488812
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for 3 months (protocol A)
Study: 1928875
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (AC) administered 15 minutes after acetaminophen
Study: 1928875
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (AC) administered 30 minutes after acetaminophen
Study: 1928875
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (AC) administered 120 minutes after acetaminophen
Study: 6869761
Drug: Rapid infusion
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid infusion of etomidate
Study: 6869761
Drug: Thiopentone bolus
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone bolus injection
Study: 27183545
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide (FAc) 0.5 µg/day
Study: 27183545
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide (FAc) 0.2 µg/day
Study: 24346280
Drug: Lapatinib administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib administered 1 h after a low-fat meal
Study: 24346280
Drug: Lapatinib administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib administered 1 h after a high-fat meal
Study: 24346280
Drug: Lapatinib administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib administered 1 h before a low-fat meal
Study: 22041970
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution (ORS) group
Study: 16636870
Drug: Clazosentan 30
Normalized name: clazosentan
DrugBank: Clazosentan (DB06677)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Clazosentan 30 mg/h for 3 h
Study: 16636870
Drug: Clazosentan 60
Normalized name: clazosentan
DrugBank: Clazosentan (DB06677)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Clazosentan 60 mg/h for 6 h
Study: 16636870
Drug: Clazosentan 30
Normalized name: clazosentan
DrugBank: Clazosentan (DB06677)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Clazosentan 30 mg/h for 12 h
Study: 16636870
Drug: Clazosentan 10
Normalized name: clazosentan
DrugBank: Clazosentan (DB06677)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Clazosentan 10 mg/h for 3 h
Study: 16636870
Drug: Clazosentan infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clazosentan infusion
Study: 16135178
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (400 microg/puff, twice daily)
Study: 8636714
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha 2a (IFN) treatment
Study: 2483687
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate 125 mg daily infusions
Study: 61439
Drug: Methyldopa ('Aldomet')
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyldopa ('Aldomet') treatment
Study: 28969327
Drug: Deep NMB
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep NMB (infusion of rocuronium 2 mg ml -1)
Study: 28969327
Drug: Standard NMB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard NMB (bolus of rocuronium 10 mg or increased depth of anaesthesia)
Study: 26255515
Drug: Auricular point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular point sticking therapy (stimulated on specific points once a week for 4 weeks)
Study: 26255515
Drug: Combined program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined program of auricular point sticking therapy and TCM psychotherapy (4 weeks treatment)
Study: 26255515
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication group (oral administration of deanxit, one tablet a day for 4 weeks)
Study: 23153291
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with wavelength 830 nm, dose of 2 J/cm² and additional spots of 1 J/cm².
Study: 23153291
Drug: Placebo light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo light treatment (control group).
Study: 22303699
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol hydrochloride sustained release tablets administered at 12h, 24h, 48h postoperation and before cleaning up procession
Study: 22303699
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no administration of Tramadol)
Study: 16684263
Drug: Iron plus
Normalized name: Nu-Iron Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron plus triple therapy for H. pylori
Study: 16054522
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition supplemented with dipeptide alanyl‐glutamine
Study: 16054522
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (standard)
Study: 7554318
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine oestrogen (1.25 mg daily)
Study: 7554318
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta‐oestradiol (100 micrograms daily)
Study: 7554318
Drug: Both oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oestrogen treatments
Study: 7554318
Drug: Neither oral
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither oral nor transdermal oestrogen
Study: 2298404
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (DOX) treatment arm (60 mg/m2 starting dose, maximum cumulative dose of 500 mg/m2)
Study: 7436691
Drug: Tryptophan (L‐tryptophan)
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tryptophan (L‐tryptophan)
Study: 22072307
Drug: Combination docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination docetaxel and carboplatin (cDC): weekly docetaxel 30 mg/m² on days 1 and 8 and carboplatin AUC = 6 on day 1, every 3 weeks
Study: 22072307
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with docetaxel then carboplatin (sDC): docetaxel 30 mg/m² on days 1 and 8 for 6 cycles followed by carboplatin AUC = 6 on day 1 for 6 cycles
Study: 20541024
Drug: High-dose steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose steroids plus a second immunosuppressive agent
Study: 17255748
Drug: Remune, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remune, an inactivated HIV‐1 vaccine
Study: 15821223
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) - continuous infusion starting with 50 mg/kg/4 h followed by 100 mg/kg/24 h for 44 h (n = 18)
Study: 8762660
Drug: Dobesilate of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobesilate of calcium with dexamethasone acetate and lidocaine (Treatment A)
Study: 8762660
Drug: Prednisolone capronate
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone capronate with dibucaine hydrochloride (Treatment B)
Study: 2496791
Drug: Omeprazole 30
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 30 mg daily for six weeks
Study: 348251
Drug: Cimetidine 1
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1 g daily for six weeks
Study: 30073267
Drug: Cochlear Implants
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear Implants (CIs)
Study: 28613971
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy Self-Help Booklet (CBT-SHB) with usual care
Study: 19714630
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) alone (> or =10 mg/m(2)/week, maximum dosage 1 mg/kg/week)
Study: 19714630
Drug: Etanercept alone
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept alone (0.8 mg/kg/week, maximum dose 50 mg)
Study: 19714630
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (MTX, etanercept, etanercept plus MTX)
Study: 17533209
Drug: TLC diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC diet plus soy nuts (25 g of soy protein and 101 mg of aglycone isoflavones)
Study: 15232517
Drug: IT 2.5
Normalized name: Procto-Kit 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT 2.5 mg levobupivacaine + 25 microg fentanyl (LF)
Study: 15232517
Drug: IT 2.5
Normalized name: Procto-Kit 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT 2.5 mg levobupivacaine (L)
Study: 10079864
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy (specific antibiotics not detailed)
Study: 10079864
Drug: Immunotherapy (immunocorrection)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (immunocorrection)
Study: 10079864
Drug: Various physiochemical
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various physiochemical methods in complex treatment
Study: 2610720
Drug: Sustained Release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained Release Capsule (Elantan), 50 mg
Study: 2610720
Drug: Sustained Release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained Release Tablet, 50 mg
Study: 2610720
Drug: Sustained Release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained Release Capsule, 100 mg
Study: 2610720
Drug: Non Sustained
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non Sustained Release Tablets, 40 mg
Study: 2610720
Drug: Non Sustained
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non Sustained Release Tablets, 2 x 20 mg
Study: 31445343
Drug: Quetiapine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine plus adjunctive personalized therapy
Study: 29088099
Drug: Anserine/carnosine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anserine/carnosine supplementation (ACS) 1.0 g (3:1) for 3 months
Study: 16145319
Drug: Transdermal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormone therapy (0.05 mg 17[beta]-estradiol every 24 hours combined with 5 mg oral dydrogesterone daily)
Study: 16145319
Drug: Oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormone therapy (2 mg 17[beta]-estradiol semihydrate every 24 hours combined with 10 mg dydrogesterone)
Study: 16145319
Drug: Transdermal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormone therapy
Study: 16145319
Drug: Oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormone therapy
Study: 16145319
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (both routes)
Study: 681999
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (5000 units)
Study: 28631179
Drug: Volasertib in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib in combination with cytarabine
Study: 28631179
Drug: Cytarabine in
Normalized name: cytarabine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytarabine in combination with volasertib
Study: 25035291
Drug: Lomustine 110
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lomustine 110 mg/m² once every 6 weeks
Study: 25035291
Drug: Bevacizumab 10
Normalized name: bevacizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 10 mg/kg once every 2 weeks
Study: 25035291
Drug: Bevacizumab 10
Normalized name: bevacizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 10 mg/kg every 2 weeks and lomustine 90 mg/m² every 6 weeks
Study: 25035291
Drug: Bevacizumab 10
Normalized name: bevacizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 10 mg/kg every 2 weeks and lomustine 110 mg/m² every 6 weeks
Study: 25035291
Drug: Bevacizumab and
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab and lomustine 90 mg/m²
Study: 18752692
Drug: Food-based intervention
Normalized name: food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food-based intervention consisting of six food items with modified cation content and 500 ml of maas (fermented milk)/d for 8 weeks
Study: 18752692
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet providing the same quantities of targeted foods but of standard commercial composition and 500 ml/d of artificially sweetened cooldrink
Study: 11137328
Drug: Oral oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestradiol (1 mg) combined with Chlormadinone Acetate 5 mg
Study: 11137328
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol 50 microg/24 h with Norethisterone Acetate (11.2 or 22.4 mg)
Study: 9186533
Drug: Conventional induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional induction treatment with daunorubicin and cytarabine
Study: 8244812
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiotherapy (daily 150-180 cGy fractions to 45-55 Gy in 5-6 weeks)
Study: 3104051
Drug: Liquid antacid
Normalized name: GNP Liquid Antacid Maximum Strength 400mg-400mg-40mg/5ml Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid antacid preparation 1
Study: 3104051
Drug: Liquid antacid
Normalized name: GNP Liquid Antacid Maximum Strength 400mg-400mg-40mg/5ml Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid antacid preparation 2
Study: 29358194
Drug: Atorvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin treatment with higher HDL cholesterol levels at month 3
Study: 26888227
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg for the first dose and then 200 mg)
Study: 26888227
Drug: Loxoprofen (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxoprofen (60 mg)
Study: 26888227
Drug: Acetaminophen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (600 mg)
Study: 24378207
Drug: DP-R206 (150-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP-R206 (150-mg ibandronate/24,000-IU vitamin D3 tablet)
Study: 24378207
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 24,000-IU tablet (reference drug)
Study: 18794697
Drug: Rectal trumpet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal trumpet
Study: 16094218
Drug: MMRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV vaccine (high potency)
Study: 16094218
Drug: MMRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV vaccine (any varicella potency)
Study: 16094218
Drug: MMRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV vaccine (1 or 2 injections)
Study: 16094218
Drug: MMRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV vaccine (second injection)
Study: 16094218
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of M-M-RII and VARIVAX
Study: 12571431
Drug: Nefazodone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone monotherapy
Study: 12571431
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with amitriptyline and haloperidol
Study: 10561963
Drug: Terbinafine cream
Normalized name: terbinafine Topical Cream
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbinafine cream for 1 week
Study: 10561963
Drug: Miconazole cream
Normalized name: Miconazole Nitrate 2% Topical application Cream [CAREALL MICONAZOLE CREAM]
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole cream for 4 weeks
Study: 8678082
Drug: TMP-SMX 160/800
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP-SMX 160/800 mg orally every 12 hours for 2 months
Study: 1773691
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Verapamil and Enalapril
Study: 27418270
Drug: Adjuvant girentuximab
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant girentuximab treatment
Study: 16710287
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of irbesartan (ARB) and ramipril (ACE inhibitor)
Study: 16710287
Drug: Ramipril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (ACE inhibitor) alone
Study: 15587588
Drug: Tyrothricin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrothricin (0.1 g tyrothricin per 100 g of vehicle) applied twice daily for 9 days
Study: 15587588
Drug: Placebo powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo powder applied twice daily for 9 days
Study: 9215784
Drug: Temporary 125I
Normalized name: fibrinogen (125I)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary 125I implants with a median reference dose of 60 Gy
Study: 9215784
Drug: Permanent 125I
Normalized name: fibrinogen (125I)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permanent 125I implants with a median reference dose of 100 Gy
Study: 9215784
Drug: Temporary implants
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary implants
Study: 9215784
Drug: 200 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 Gy isodose volume <4.5 ml
Study: 9215784
Drug: 200 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 Gy isodose volume >4.5 ml
Study: 8485323
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (PN) with high lipid content
Study: 3609119
Drug: 5-FU 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU 7.5 mg/kg
Study: 3609119
Drug: 5-FU 15
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 15 mg/kg
Study: 3609119
Drug: 5-FU 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU 7.5 mg/kg and 15 mg/kg
Study: 29080044
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg twice a day for 3 months
Study: 29080044
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice a day for 3 months
Study: 20621334
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups aggregated
Study: 18676087
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg micronized progesterone for 21 days
Study: 16361638
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 150 U/kg subcutaneously 3 times weekly until 3 weeks after completion of chemotherapy
Study: 8160250
Drug: Oral fluphenazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluphenazine dihydrochloride 5 mg
Study: 8160250
Drug: Oral fluphenazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluphenazine dihydrochloride 10 mg
Study: 8160250
Drug: Oral fluphenazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluphenazine dihydrochloride 20 mg
Study: 3292710
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 40 mg orally four times daily